{"name":"ChromaDex, Inc.","slug":"chromadex-inc","ticker":"","exchange":"","domain":"chromadex.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxPalFmRmpfdnBwX2pxdlN2am5NWU1lVG1YQmNIZGQ0dW1BeE5ScmE0cnhxRWF2ZUhIME9UOEp4TWFQM21OQ1pMWjZjdzFlTmZ0TW9ta2tIVU1yZjRBazhQWTNoVmxJaDdZTlpWTG41V0N3Q0JFUU0xSUo3OEtLbWIzQjV1d01ITTltc2MzYmdydk5OTmxtcUZzRUNNcGlEbE9kRGhiem9qZW5PTkl4TjY1Y0xnLWRVSHYwdmNNNEpHemlsSldrMUJiNEtkaXVEdXlwQUx3ZGpvb2tzMGlaZTNzUUJ3?oc=5","date":"2026-02-27","type":"pipeline","source":"The Globe and Mail","summary":"Niagen Bioscience Divests Non-Core Analytical Standards Business - The Globe and Mail","headline":"Niagen Bioscience Divests Non-Core Analytical Standards Business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxQSk5CSTBxRTNjZ012WWl3ZWxoZ2lhVnlTbnRwNDEwMFFwSmZuWm5XNUNyMFdKUnFDQzBGWDd5VVFWQ2ZQOVRQbV8zZV9UbEhVY2lXb2VuSGRHWURvNEpoOXZCRkhKbzlkNHg1WUN6QzVTWEphYUVGX3E5eTZxakkzRkNqaEtaTHFkVDVHVGs0ZThzajk5R0Rqd1NzaV9xUFFmeWFSd2F6b0swbHF1MnE5ZGRPRUVrZnItR0tNRDFvb0pXOWlrci1fY0JkSXd5S3ZXVTdPSDU0ZlI2bEU2ZEF1VHhDTnAySGpHcmtSU2dub3RyVEFEOVNkQktRN2thbER0aFpheFF5YzVUc2JjdHdsYkwzUUxpS29uMnBpTHpGamFJNG12TWpj?oc=5","date":"2026-02-26","type":"pipeline","source":"Business Wire","summary":"Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction - Business Wire","headline":"Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNUGVNRmV1T0d2Z1ppWTdSR19paU40TzhUWDlJZlAwMGQtcUxBMzJVMkFWcHhOTElBaFdJSDRBSnU2dmxKV3BSak12ckRvV0llNjNwMnJaWU96ajBEX0c5UEVFeE9jb2sza2lCSUkxdGp2cFQ2UHdtREJDSGV1eTlmZEhxek8xUVJRSUpmSS1MWThaQ2RaLVlR?oc=5","date":"2025-10-01","type":"pipeline","source":"Yahoo Finance","summary":"Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide - Yahoo Finance","headline":"Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than ","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-08","type":"deal","source":"Business Wire","summary":"Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Hauk","headline":"Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Ribos","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOWmRjUE1YUzc0WmZ1aVc1QnVhU2pKMU9XX1RSZ3dqTVlfcUlRRi1WclVfdFlxdjB1TU8zeDVOaU53bE13emxJRWpGZkhmNC05dUZQWjRXR1NQR2o5eFF5ZHJDSkc5SWsxal95anNqa3pKa05yZENGSXM0VXMxZ2FZQ0RhOElkWWxxRHdjbWh0VVU2VnhNLXlwd3htUjlGd3RxQWY1SWZmZjJJZ05MZWtpeHpMUHc?oc=5","date":"2025-04-08","type":"regulatory","source":"BioSpace","summary":"Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs - BioSpace","headline":"Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxPREplRHR0bk1DT2xiTGRDa2RWMndZVzlpSW9GcDNpYlk2ZUlLVnRtV3pIcjNwUWRKSUp3TXItUW9NTFJsZGlLVHYwWlpyT1hIMmFGWXJPVzlOZVJLXzFCRmQ2Q2pUbXUzOXVPYkNSMktSdVFwMlVzUlV6Z210VVVpazdoOFlIZjZjZFNxN1pQV3Q4VHdrY09LWTJoT2hpZmFGU1l5SHFTMzh1empaZU9zV0Y5elRNZ1JVaHhCdG85amJYelJYTF84bFBxbWlneDgtczh3TFhXdDlCNkZGc3JCNUhyUmtpVWdVcTZWdHZqVVcwY21ZUGN6VVpWSHdxMEM5M0E?oc=5","date":"2025-03-14","type":"pipeline","source":"Citeline News & Insights","summary":"ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+ - Citeline News & Insights","headline":"ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+ - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOeDBobDQ3QXVpSTA2QXlHSlE0UjVaZkNEeDZDZU9KNnp4VUVlVUZFUVVnYmMzcUhpUnZ1akdJb25BRk9jbUZXSU9pQ0JVb0d0TGtJZEtuaGdmbWdrX2k4YThNVlJ0X1VDTHh4LUw5aEZjMmt2dFVsZHFwY0tlQUc1Tnd6ODRYbW5RWjhMRk9tT2kxYjZlSVl4SnZEZWhyU2Q2eENDdlpUOHAzT0k?oc=5","date":"2025-03-06","type":"regulatory","source":"Seeking Alpha","summary":"ChromaDex Capitalizes On Longevity Boom, But Valuation Remains High - Seeking Alpha","headline":"ChromaDex Capitalizes On Longevity Boom, But Valuation Remains High","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5PcHk4YW1RR0RGdGZhSEFTUDg3aUNyLTd4MW5KTFlNMjU0UnAtQUFaOUotQXU1SlVIZEJ4YjkzZXJaYnFnVVhHZmxUdkhaOGxIazZCUURwOFEzTVltQWxLVUlEUzQyZXVlLUR6a0lGWHhOWTR4QUpvV2xwR0dMUQ?oc=5","date":"2025-03-04","type":"earnings","source":"Yahoo Finance","summary":"ChromaDex Corp (CDXC) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advances - Yahoo Finance","headline":"ChromaDex Corp (CDXC) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advances","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNNFJmSXlvQmp6NjVNNUlNN1F5M3hCQzk4RW5fdENZMlk2STE0M29oOEZkN1l0eFAta1ZvQ1pGc21CajJSTThwUW14MnBCeFNMd05Ib1dnU0wtNTBycU8xdnZIS1Z2STBtTVVJTXc2ZzZteFJ1NmFlZG11Qk9TTHlqX0s4bGQzZHFmWHFnWU5KdS1KWW8wN3pueg?oc=5","date":"2024-09-12","type":"deal","source":"supplysidesj.com","summary":"ChromaDex, JQMS Partner for GMP Compliance Services - supplysidesj.com","headline":"ChromaDex, JQMS Partner for GMP Compliance Services","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxQMS1CN3ZjODJ2WGdNM1pvVWNNcjBEY2h3WDhDRGhQUE1Qd0FTcV9jckZ6TFpNZUNhd0ZKSjh4bmY4THNUVU0xV00zeERfU29xb0l3SGdxbk1EbWM5c3FWdXVtYm9OVG43UXdtWEFNRThvRmh2NG9xRFlrX2pUQzY1MWQzVnprS1FNTmtqS0d1Z1JDNmFWTUYzWjhlNFRsTi1INDRvalNsMUt6a0t1ZWdlTm1zbzZ5QTN1YlM5Zm5hTHZKWXBWNHNqQlB5RURkUjV0dV9aTHluN1Fta2FBdnBCWFhReFlkbll5R1RCLXRucVhJTGU1TFp6SUk3YXAyQWFaYzF2WWh4U0Y5akph?oc=5","date":"2024-07-16","type":"pipeline","source":"Business Wire","summary":"ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen - Business Wire","headline":"ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOQkNMUnYzU09ZMWlCWUctS1V6RXducDB0dWlfYW03NUFEbHA2NTEzazJkakdtWGFBNUlCYUxBYndWSDh0dGdFeXBIUXRwQmZ4eWRnZk42Z1ZRVjlMMnZvdzJLZV9qRldvQ2gzb0lENWt6Nl9sTFUyOXZZNkNPbElqRUF0Y3VyTU1FWGNJQg?oc=5","date":"2024-02-05","type":"regulatory","source":"supplysidesj.com","summary":"ChromaDex sides with FDA, pharma in NMN supplements debate - supplysidesj.com","headline":"ChromaDex sides with FDA, pharma in NMN supplements debate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNYzFfdkdBdDFZaUdEM2JtZWxkUFctYmQ2cDMyWEd4V3VweWNzZ1c1WkpjSE5lN3B2RlhaNXVneEtfRzd3Q0dPNm5ZSHBiMldXdHBsUmQ4WFQtVmYtSmIwZGZkeDFzWDZocjRFUVVVS09xbXNKOE1wNmxZa2s0Sm03cE41RThaZGZLWjZCV3FxUTJXaTk4Y2k3TTc3cFNMYmdCUXc?oc=5","date":"2023-02-13","type":"patent","source":"IPWatchdog.com","summary":"CAFC Says ChromaDex Patent Claiming Isolated Form of Vitamin B3 Fails Under 101 - IPWatchdog.com","headline":"CAFC Says ChromaDex Patent Claiming Isolated Form of Vitamin B3 Fails Under 101","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}